艾伯塞拉生物
ABCL
11.80
-0.88
-6.94%
艾伯塞拉生物
US · ABCL
#2215 按市值排名
上市于 2020
11.80
-0.88
-6.94%
实时 - 追踪5344个代码 - 心跳于500秒前
· 2026-10-16 19:59
✦ 量化股权信号 计算方式说明
减持
- 机构持股总比例下降了2.1个百分点。
机构持股
- 机构持股比例
- 36.75% -2.15pp
- 机构数量
- 161
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Individual/Insider21.64%
Hedge Fund16.29%
Mutual Fund13.78%
Public Company5.63%
Private Company0.61%
Family Office/Trust0.31%
Government Pension Fund0.12%
Other41.61%
主要股东 截至 2026-04-01
Carl Hansen
17.60% · 57.03M 股
Baker Bros. Advisors LP
10.19% · 33.01M 股
Capital Research
4.19% · 13.59M 股
Two Sigma Investments, LP
3.22% · 10.44M 股
Veronique Lecault
2.97% · 9.61M 股
The Toronto-Dominion Bank
2.95% · 9.57M 股
UBS Asset Management
1.91% · 6.19M 股
Bank of America Corporation
1.90% · 6.14M 股
ArrowMark Colorado Holdings, LLC
1.27% · 4.11M 股
BlackRock
1.17% · 3.81M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 45次买入 · 4次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Carl Hansen | CEO, President & Chairperson | 17.60% |
| Veronique Lecault | Chief Operating Officer | 2.97% |
| Michael Hayden | Lead Independent Director | 0.46% |
| Stephen Quake | Independent Director | 0.34% |
| Andrew Booth | Chief Financial Officer | 0.19% |
| John Montalbano | Independent Director | 0.08% |
| Tryn Stimart | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary | 0.00% |
| Lynn Seely | Independent Director | -- |
| Wen-Chaun Lo | Independent Director | -- |
| Victor Sandor | Independent Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-23 | Michael Hayden | Lead Independent Director | Open Market Acquisition | +53,613 | $10.64 |
| 2026-08-17 | John Montalbano | Independent Director | Open Market Acquisition | +10,000 | $11.03 |
| 2026-08-13 | Andrew Booth | Chief Financial Officer | Private Acquisition | +37,200 | $10.32 |
| 2026-08-11 | Michael Hayden | Lead Independent Director | Open Market Acquisition | +46,387 | $10.37 |
| 2026-08-10 | Michael Hayden | Lead Independent Director | Other Disposition | -50,000 | -- |
| 2026-06-30 | Lynn Seely | Independent Director | Other Derivative Acquisition | +152,207 | $7.85 |
| 2026-06-30 | Victor Sandor | Independent Director | Other Derivative Acquisition | +152,207 | $7.85 |
| 2026-06-10 | Stephen Quake | Independent Director | Other Derivative Acquisition | +111,701 | $5.27 |
| 2026-06-10 | Michael Hayden | Lead Independent Director | Other Derivative Acquisition | +111,701 | $5.27 |
| 2026-06-10 | John Montalbano | Independent Director | Other Derivative Acquisition | +111,701 | $5.27 |
| 2026-06-02 | Andrew Booth | Chief Financial Officer | Derivative Exercise and Retained | +250,000 | $0.19 |
| 2026-05-13 | John Montalbano | Independent Director | Open Market Acquisition | +20,000 | $4.77 |
| 2026-02-26 | Carl Hansen | CEO, President & Chairperson | Open Market Acquisition | +38,000 | $3.44 |
| 2026-02-26 | Andrew Booth | Chief Financial Officer | Open Market Acquisition | +42,600 | $3.42 |
| 2026-02-25 | Carl Hansen | CEO, President & Chairperson | Open Market Acquisition | +177,457 | $3.27 |
| 2025-12-31 | Carl Hansen | CEO, President & Chairperson | Other Derivative Acquisition | +2,106,505 | $3.42 |
| 2025-12-31 | Tryn Stimart | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary | Other Derivative Acquisition | +539,265 | $3.42 |
| 2025-12-31 | Andrew Booth | Chief Financial Officer | Other Derivative Acquisition | +808,898 | $3.42 |
| 2025-12-31 | Veronique Lecault | Chief Operating Officer | Other Derivative Acquisition | +539,265 | $3.42 |
| 2025-12-17 | Carl Hansen | CEO, President & Chairperson | Other Disposition | -225,000 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:59:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
艾伯塞拉生物 讨论区 0 条评论